

**FORM 7**

**MONTHLY PROGRESS REPORT**

**April 2018**

Name of CSE Issuer	EVITRADE Health Systems Corp. (formerly, Auxellence Health Corporation), (the "Issuer")
Trading Symbol	EVA
Number of Issued Listed Securities	36,390,265
Number of Issued Outstanding Options	Nil
Number of Shares Reserved for Issuance	16,608,440 (from Warrants)
Number of Units Reserved for Issuance	1,400,000 (from Secured Credit Loan)
Number of Units Reserved for Issuance	1,103,575 (from Debt Settlement)
Date	May 6, 2018

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by the CSE Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the theCSE.com website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the CSE Policies. The discussion in this report must be factual, balanced and non-promotional.

**General Instructions**

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term “Issuer” includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

## Report on Business

1. Provide a general overview and discussion of the development of the Issuer’s business and operations over the previous month. Where the Issuer was inactive disclose this fact.

In April the company has continued to explore other opportunities for the TULIP(TM) technology and any healthcare related encryption – blockchain technology.

Provide a general overview and discussion of the activities of management.

Management continues to pursue opportunities in the healthcare business. While the primary focus is still on customizing hardware technologies and software applications towards providing personalized health solutions for common health issues, management has been exposed to and presented with a number of health/medical opportunities, interesting software technologies, and other potential businesses. The Company also continues to evaluate business opportunities in an endeavour to increase shareholder value. During April 2018 the company continued to conduct meetings for due diligence in connection to the potential acquisition of Cantech Molecular, Artillery Labs and has evaluated a number of other health and technology opportunities. Management has also continued negotiating with the owners of Decanex Inc. to deal with the status of the TULIP(TM) development, how to handle the advancement of notes or funds for engineering, the IP surrounding the development of the TULIP system not captured by the original patent and any other outstanding items related to the TULIP(TM) system). The company has been meeting with corporate finance advisory companies to discuss business development. The company signed that it has continued the financial advisory engagement with Haywood Securities to assist in developing its business opportunities. The company also announced that it has come to a definitive terms with Artillery Labs. There are no other matters to report.

Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

None to report.

2. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

Due to funding shortages for the TULIP project the operator has stopped services.

3. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

None to report.

4. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

None to report for this month.

5. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

The Issuer continued with its financial advisory engagement with Haywood Securities and issued 1 million shares under the terms of the agreement.

The Issuer also came to a definitive agreement with Artillery Labs and issued 5 million shares of the company with its final release being subject to performance milestones.

6. Describe the acquisition of new customers or loss of customers.

None to report.

7. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trademarks.

None to report.

8. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

None to report.

9. Report on any labour disputes and resolutions of those disputes if applicable.

None to report.

10. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

None to report.

11. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

The Issuer had approximately CDN\$1,171,615 plus USD\$24,950 in cash debt/loan advances owed to directors of the company.

The Issuer also had a total of \$74,851 of cash debt/loan advances from related party creditors.

The Issuer also has US\$10,000 of cash loans advanced from a related party creditor.

The Issuer also has US\$90,000 of cash loans advanced from a non-related parties

The Issuer has \$1,537,787.50 in cash debt loaned to the company by non-related parties.

12. Provide details of any securities issued and options or warrants granted.

n/a

13. Provide details of any loans to or by Related Persons.

Loans from directors, for approximately CDN\$946,615 and USD\$24,950 of funds/loans to the company at of the date of this statement.

The Issuer also has \$74,851 of debt owed to related party creditors and approximately \$827,681 in convertible debt owed to the company's operator from the debt settlement.

The Issuer also has US\$10,000 of debt owed to a related party creditor.

14. Provide details of any changes in directors, officers or committee members.

None to report.

15. Discuss any trends, which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

None to report.

## Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer, which has not been publicly disclosed.
3. The undersigned hereby certifies to CNSX that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all CNSX Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: May 6, 2018.

Sydney Au  
Name of Director or Senior Officer

"Sydney Au"  
Signature

President and CEO  
Official Capacity

<b>Issuer Details</b>	For Month End	Date of Report
Name of Issuer EVITRADE Health Systems Corp. (formerly, Auxellence Health Corporation)	April 2018	May 6, 2018
Issuer Address c/o Mr. Faisal Manji, CFO / Sydney Au, CEO #168-11280 Twigg Place		
City/Province/Postal Code Richmond, BC, V6V 0A6	Issuer Fax No. N/A	Issuer Telephone No. (604) 780-3311
Contact Name Sydney Au	Contact Position President & CEO	Contact Telephone No. (604) 780-3311

Contact Email Address: <a href="mailto:ceo@auxellence.com">ceo@auxellence.com</a>	Web Site Address <a href="http://www.auxellence.com">www.auxellence.com</a>	